On Monday, HSBC (LON:HSBA) updated its stance on ICICI Bank (ICICIBC:IN) (NYSE: IBN) shares, increasing the price target to INR1,520 from INR1,460, while reiterating a Buy rating for the stock. The revision reflects HSBC's positive outlook on the bank's performance and its subsidiaries' growing value.
The bank's strong delivery on all metrics when compared to its larger peers was cited as a key reason for the price target raise. HSBC's analyst believes that ICICI Bank's superior performance justifies a higher premium, leading to the valuation of the bank at 3x its forecasted FY26 book value per share (BVPS), up from the previous 2.9x.
Additionally, the increased value creation by ICICI Bank's subsidiaries has been recognized in the revised target price. HSBC has aligned its valuation multiple for ICICI Prudential (LON:PRU) Life Insurance (IPRU IN) and ICICI Lombard General Insurance (ICICIGI IN) following their recent results, indicating a positive reassessment of these businesses.
The asset management and broking arms of ICICI Bank have also contributed to the upgraded target price. HSBC highlights the asset management business's superior assets under management (AUM) and profit after tax (PAT) growth, as well as the broking business's accelerated earnings growth as factors supporting the price target increase.
HSBC's new price target implies an approximate 21% upside from the current trading price of ICICI Bank's shares, signaling confidence in the bank's future performance and its ability to continue delivering value to its shareholders.
"In other recent news, ICICI Bank has reported a significant increase in its consolidated profit after tax in its annual report filed with the U.S. Securities and Exchange Commission. Under Indian GAAP, the profit rose to Rs. 44,256 crore (US$ 5,310 million) in fiscal year 2024, while under U.S. GAAP, net income increased to Rs. 61,376 crore (US$ 7,365 million). Furthermore, the bank's stockholders’ equity, as per U.S. GAAP, stood at Rs. 310,990 crore (US$ 37.3 billion).
In terms of analyst ratings, Kotak has reiterated its Buy rating for ICICI Bank, maintaining a price target of INR1,400.00. Axis Capital (NYSE:AXS) Limited adjusted its stance on ICICI Bank from 'Buy' to 'Add' due to consistent earnings growth, while Jefferies, Citi, and CLSA maintained 'Buy' ratings.
Other recent developments include changes in key management positions and potential fundraising through the issuance of debt securities.
Additionally, ICICI Bank's commitment to environmental, social, and governance standards has been recognized, and it is assured that a warning from the Securities and Exchange Board of India regarding its handling of the delisting process of ICICI Securities Limited's equity shares will not impact its financial or operational activities."
InvestingPro Insights
ICICI Bank's strong performance, as highlighted by HSBC's analysis, is further supported by real-time data from InvestingPro. The bank's market capitalization stands at an impressive $107.92 billion, reflecting its significant presence in the financial sector. ICICI Bank's revenue growth of 24.62% over the last twelve months and a quarterly growth of 27.37% as of Q2 2025 underscore its robust financial performance, aligning with HSBC's positive outlook.
InvestingPro Tips reveal that ICICI Bank has raised its dividend for 4 consecutive years, with a current dividend yield of 0.68%. This consistent dividend growth, coupled with a strong return over the last five years, supports HSBC's view on the bank's value creation for shareholders.
The bank's P/E ratio of 18.98 and Price to Book ratio of 3.24 suggest that investors are willing to pay a premium for ICICI Bank's shares, which is in line with HSBC's decision to value the bank at 3x its forecasted FY26 book value per share. Additionally, ICICI Bank's operating income margin of 31.2% indicates efficient operations, further justifying HSBC's bullish stance.
For investors seeking more comprehensive insights, InvestingPro offers 8 additional tips for ICICI Bank, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.